Incidence of second neoplasm in childhood cancer survivors treated with GH: An analysis of GeNeSIS and HypoCCS

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages 565-573

  Woodmansee, Whitney W ^a   Zimmermann, Alan G ^b   Child, Christopher J ^b   Rong, Qi ^b   Erfurth, Eva Marie ^c   Beck Peccoz, Paolo ^d   Blum, Werner F ^e   Robison, Leslie L ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF MILAN   (Italy)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DATA ANALYSIS; DRUG SAFETY; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SECOND CANCER;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INCIDENCE; MALE; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS; TREATMENT OUTCOME;

EID: 84875127775     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0967     Document Type: Article

References (30)

1. Alvarez JA, Scully RE, Miller TL, Armstrong FD, Constine LS, Friedman DL & Lipshultz SE. Long-term effects of treatments for childhood cancers. Current Opinion in Pediatrics 2007 19 23-31. (doi:10.1097/MOP.0b013e328013c89e)
2. Mulder RL, Kremer LC, van Santen HM, Ket JL, van Trotsenburg AS, Koning CC, Schouten-van Meeteren AY, Caron HN, Neggers SJ & van Dalen EC. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treatment Reviews 2009 35 616-632. (doi:10.1016/j.ctrv.2009.06.004)
3. Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H & Muller J. Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clinical Endocrinology 2000 53 191-197. (doi:10.1046/j.1365-2265.2000.01079.x)
4. Gurney JG, Ness KK, Sibley SD, O'Leary M, Dengel DR, Lee JM, Youngren NM, Glasser SP & Baker KS. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006 107 1303-1312. (doi:10.1002/cncr.22120)
5. Clayton PE, Banerjee I, Murray PG & Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nature Reviews. Endocrinology 2011 7 11-24. (doi:10.1038/nrendo.2010.171)
6. Samani AA, Yakar S, LeRoith D & Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 2007 28 20-47. (doi:10.1210/er.2006-0001)
7. Key TJ, Appleby PN, Reeves GK & Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncology 2010 11 530-542. (doi:10.1016/S1470-2045(10)70095-4)
8. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. International Journal of Cancer 2010 126 1702-1715. (doi:10.1002/ijc.24927)
9. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C,Weiss NS, Fitzpatrick A et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Annals of Internal Medicine 2008 149 461-471.
10. Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser GM & Monson JP. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clinical Endocrinology 2005 63 274-279. (doi:10.1111/j.1365-2265.2005.02338.x)
11. Jostel A, Mukherjee A, Hulse PA & Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clinical Endocrinology 2005 62 698-705. (doi:10.1111/j.1365-2265.2005.02282.x)
12. Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Haggstrom M & Ranke MB. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism 2010 95 4449-4454. (doi:10.1210/jc.2010-0287)
13. Svensson J, Bengtsson BA, Rosen T, Oden A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312. (doi:10.1210/jc.2003-031601)
14. Swerdlow AJ, Higgins CD, Adlard P & Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002 360 273-277. (doi:10.1016/S0140-6736(02)09519-3)
15. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, Brada M, Hayward RD, Brook CG et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. Journal of Clinical Endocrinology and Metabolism 2000 85 4444-4449. (doi:10.1210/jc.85.12.4444)
16. Wilton P, Mattsson AF & Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). Journal of Pediatrics 2010 157 265-270. (doi:10.1016/j.jpeds.2010.02.028)
17. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM & Robison LL. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. European Journal of Endocrinology 2011 165 217-223. (doi:10.1530/EJE-11-0286)
18. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL & Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. Journal of Clinical Endocrinology and Metabolism 2006 91 3494-3498. (doi:10.1210/jc.2006-0656)
19. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y & Robison LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. Journal of Clinical Endocrinology andMetabolism2002873136-3141. (doi:10.1210/jc.87.7.3136)
20. Webb SM, Strasburger CJ, Mo D, Hartman ML, Melmed S, Jung H, Blum WF & Attanasio AF. Changing patterns of the adult growth hormone deficiency diagnosis documented in a decadelong global surveillance database. Journal of Clinical Endocrinology and Metabolism 2009 94 392-399. (doi:10.1210/jc.2008- 0713)
21. Louis DN, Ohgaki H,Wiestler OD, CaveneeWK, Burger PC, Jouvet A, Scheithauer BW & Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007 114 97-109. (doi:10.1007/s00401-007-0243-4)
22. Blum W & Schweizer R. Insulin-like growth factors and their binding proteins. In Diagnostics of Endocrine Function in Children and Adolescents, pp 166-199. Ed. M Ranke, Basel: S. Karger, 2003.
23. Blum WF & Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regulation 1994 4 (Suppl 1) 11-19.
24. Boettcher C, Schaefer M, Wudy SA & Blum WF. Cross-calibration of IGF-I and IGFBP-3 assays to obtain comparable values. Hormone Research 2006 65 178 (abstract).
25. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD & Brennan MF. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. Journal of the American Statistical Association 1993 88 400-409. (doi:10.1080/01621459.1993.10476289)
26. Inskip PD, Ries LAG, Cohen RJ & Curtis RE. New malignancies following childhood cancer. In New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000, pp 465-482. Eds RE Curtis,DMFreedman, E Ron, LAG Ries, DG Hacker, BK Edwards, MA Tucker & JF Fraumeni, Bethesda: National Cancer Institute, NIH Publ. No. 05-5302, 2006.
27. Jazbec J, Ecimovic P & Jereb B. Second neoplasms after treatment of childhood cancer in Slovenia. Pediatric Blood & Cancer 2004 42 574-581. (doi:10.1002/pbc.20025)
28. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM & Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. Journal of Clinical Endocrinology and Metabolism 2011 96 2756-2761. (doi:10.1210/jc.2011-0112)
29. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. Journal of the American Medical Association 2007 297 1207-1215. (doi:10.1001/jama.297. 11.1207)
30. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Journal of the National Cancer Institute 2006 98 1528-1537. (doi:10.1093/jnci/djj411)